Last reviewed · How we verify
CD7CAR T cells
At a glance
| Generic name | CD7CAR T cells |
|---|---|
| Sponsor | iCell Gene Therapeutics |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases (PHASE1, PHASE2)
- Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases (NA)
- CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma (PHASE1)
- Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |